Posted by Michael Wonder on 03 Sep 2016
Drug appraisal issues must be resolved at policy level
23 August 2016 - Gornall and colleagues’ investigation shows that stakeholders blame NHS England for slow and limited access to new hepatitis C medicines.
However, NHS' tactics reflect a fundamental challenge that the medicines appraisal system in England faces: the new hepatitis C medicines have, in one fell swoop, challenged the cost effectiveness paradigm that is perceived as …
